News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
March, 2025
March 2025
M T W T F S S
 12
3456789
10111213141516
17181920212223
24252627282930
31  
New 2025-2027 committee nominations are now open – IASLC
IASLC/X
Feb 10, 2025, 18:17

New 2025-2027 committee nominations are now open – IASLC

International Association for the Study of Lung Cancer shared a post on X:

“Calling all IASLC members! Your voice matters in shaping the future of thoracic cancer care. Nominate yourself or a colleague for an IASLC committee and help drive innovation in research and patient care.

Apply now.”

More posts featuring IASLC.

cancer committee nominations IASLC International Association for the Study of Lung Cancer OncoDaily Oncology
Special Coverage
Blog
Mar 12, 2025, 10:40
Introducing AIEOP'S 2024-2027 Working Group Coordinators - Simone Cesaro
Blog
Mar 12, 2025, 10:36
Yan Yin Lim has been appointed as SIOP Asia Executive Board Member
Blog
Mar 12, 2025, 10:29
Narjust Florez: Florez Lab is hiring
Science
Mar 12, 2025, 10:25
Dégi László Csaba: Awareness of Genomic Testing Among Patients with Breast Cancer in Europe
Career
Mar 12, 2025, 10:20
Jaclyn Thompson was appoined as manager of hospitality and patient transportation - City of Hope | Orange County
Science
Mar 12, 2025, 10:16
Ruben Mesa: Pelabresib plus Ruxolitinib for JAKi naive Myelofibrosis
Blog
Mar 12, 2025, 10:14
Ramy Sedhom: Very inspired after reviewing Symptom Science and Supportive Care abstracts for ASCO25
Blog
Mar 12, 2025, 10:09
Discussing prognosis with patients living with advanced cancers - Common Sense Oncology
Science
Mar 12, 2025, 10:06
Michelle Leung: Experimental models and high-throughput sequencing in metastasis research
Blog
Mar 12, 2025, 09:59
AACR Cancer and Biomedical Research Career Fair
Science
Mar 12, 2025, 09:58
Myeloma Paper of the Day, March 12th, suggested by Robert Orlowski
Science
Mar 12, 2025, 09:53
Teresa Amaral: Adjuvant Treatment for Stage III BRAF V600-Mutated Melanoma